AGN still can make money on its Botox cosmetic and therapeutic products, which the company states will see a sales increase of nearly 10% in 2013. You can read all about AGN's fourth-quarter 2012 operating results by visiting the company's consciously creative Web site.
Looking at the company's five-year chart is an exercise in illustrating the success of this Irvine, Calif.-based health-care colossus founded back in 1948. It also shows the growth of its trailing-twelve-month free cash flow that allowed it to make the two accretive acquisitions totaling over $1.3 billion.
The stock appears to be consolidating after its amazing recent peak. On Thursday AGN shares pulled back by more than 2% on higher than normal volume. Again, no problem, because analysts from Citigroup raised the price target for Allergan up to $124 citing strong growth in the company's core franchises, and kept a Buy rating on the stock.
Earlier, Argus Research lifted its target on Allergan to $118 on the premise that the company reported solid sales and earnings growth and has a strong pipeline. The firm expects the company to generate double-digit earnings growth during the next three to five years, driven by a number of important factors. It maintains a Buy rating on the shares. Do your own due diligence before investing in AGN. From a technical basis it wouldn't surprise this analyst to see the stock head closer to $100 before heading higher, as this technical chart suggests based on the Bollinger Bands, the 200-day moving average line and the Relative Strength Indicator. The RSI may be in the process of going a bit lower. AGN is a company that is solving problems with a prescient, new level of consciousness and the leadership acumen that will "ring the register" time and time again in the months ahead. At the time of publication the author had no position in any of the stocks mentioned. Follow @m8a2r1 This article was written by an independent contributor, separate from TheStreet's regular news coverage. Make smarter trading decisions and provide investment ideas that could help make you richer. Bryan Ashenberg does the dirty work so you don't have to!
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV